Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present ALR Technologies, Inc. (OTC: ALRT).

Full DD Report for ALRT

You must become a subscriber to view this report.


Recent News from (OTC: ALRT)

ALR Technologies Announces That Its ALRT Diabetes Solution Has Been Developed to an Enterprise-Scale
The ALRT Diabetes Solution is an enterprise-scale product that allows healthcare systems to implement best practices for diabetes care on large populations of patients - saving lives and money. “REPRESENTS A FUNDAMENTAL SHIFT IN DIABETES CARE” Company assembles...
Source: GlobeNewswire
Date: May, 14 2018 08:08
260 Marijuana Stocks: Equal-Weighted Portfolio Up Nearly 7% For The Week Ending January 19, 2018
I Still Day-Trade and Like the Marijuana Sector, but I Want a Bit of Safety, as Well As we prepare for 3 or 4 Federal Reserve interest rate increases for calendar year 2018, I am easing out of my Fidelity mutual funds. At the age of 60, I find myself focusing on capital preservation, and w...
Source: SeekingAlpha
Date: January, 22 2018 05:36
The ALRT Diabetes Management System in Action
RICHMOND, VA --(Marketwired - October 23, 2017) - Following the recent FDA clearance of the Company's Insulin Dose Adjustment feature and release of its patent pending Predictive A1C innovation, ALR Technologies Inc. ("ALRT" or the "Company") has released a new video presentation to show ...
Source: Marketwired
Date: October, 23 2017 08:45
The ALRT Diabetes Management System
RICHMOND, VA --(Marketwired - October 16, 2017) - Following the recent FDA clearance of the Company's Insulin Dose Adjustment feature, ALR Technologies Inc. ("ALRT" or the "Company") is releasing details of its patent pending Predictive A1C innovation added to the ALRT Diabetes Management...
Source: Marketwired
Date: October, 16 2017 08:30
FDA launches pre-certification program for developers of healthcare-related software
The FDA names nine companies that will participate in its pilot program to precertify healthcare software developers with the aim of potentially reducing the amount of information the agency requires for review. The agency says the initiative will be a tailored approach toward digital heal...
Source: SeekingAlpha
Date: September, 26 2017 15:41
ALRT Adding International Reference Dosing to Insulin Dose Adjustment (IDA) Feature for International Market Expansion
RICHMOND, VA --(Marketwired - September 25, 2017) - On September 18, 2017, the United States Food and Drug Administration (FDA) granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system. The A...
Source: Marketwired
Date: September, 25 2017 08:00
FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature
RICHMOND, VA --(Marketwired - September 19, 2017) - The United States Food and Drug Administration (FDA) has granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system. The ALRT system with ID...
Source: Marketwired
Date: September, 19 2017 10:02
ALR Technologies Reducing Its Operating Budget
RICHMOND, VA --(Marketwired - January 15, 2016) - ALR Technologies Inc. (OTC PINK: ALRT) The Company is approaching the borrowing limit of its line of credit arrangement with the Chairman of the Board. The Company has not been successful in finding follow-on financing and accordingly wi...
Source: Marketwired
Date: January, 15 2016 18:00
ALRT Introduces Value Pricing for Diabetes Management
RICHMOND, Va., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Medical practices, health insurers, self-insured employers, and other potential users of the ALRT diabetes management system can now choose a pricing plan linked to declines in a patient's A1C level. The plan is designed to eliminate performa...
Source: GlobeNewswire
Date: December, 22 2015 09:25
ALRT System Significantly Lowers A1C Levels in Type 2 Diabetes Patients in Real World Pilot Program
RICHMOND, Va., Nov. 17, 2015 (GLOBE NEWSWIRE) -- A 10-month pilot of the ALRT remote monitoring system for diabetes by the Kansas City Metropolitan Physician Association (KCMPA) has found significant improvement in glycemic control for those patients who used the system compared to those wh...
Source: GlobeNewswire
Date: November, 17 2015 09:37

 


About ALR Technologies, Inc. (OTC: ALRT)

Logo for ALR Technologies, Inc. (OTC: ALRT)

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with diabetes. ALRT has developed the FDA cleared Health e Connect System which uploads the data from blood glucose meters onto a secure website where clinicians and Diabetes Care Facilitators can better monitor and coordinate the care of diabetes patients. ALRT s system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers.

 

Contact Information

 

 

Current Management

  • Sidney Chan / CEO, CFO, Treasurer
    • Mr. Chan has been involved in managing and developing ALR Technologies since August and was instrumental in taking the company public. Prior to ALR, Mr. Chan had an extensive background in structured finance as President and CEO of the Knight s Group of Companies. Prior to the founding of the Knight s Group of Companies Mr. Chan worked for the predecessor companies of RBC Dominion Securities as well as Cominco, the mining subsidiary of Canadian Pacific. Mr. Chan is an engineer who obtained his Bachelor of Engineering degree with the distinction in Mineral Economics from McGill University.
  • Sidney Chan / Chairman
    • Mr. Chan has been involved in managing and developing ALR Technologies since August and was instrumental in taking the company public. Prior to ALR, Mr. Chan had an extensive background in structured finance as President and CEO of the Knight s Group of Companies. Prior to the founding of the Knight s Group of Companies Mr. Chan worked for the predecessor companies of RBC Dominion Securities as well as Cominco, the mining subsidiary of Canadian Pacific. Mr. Chan is an engineer who obtained his Bachelor of Engineering degree with the distinction in Mineral Economics from McGill University.
  • Ronald Cheng /
  • Kenneth Robulak / Director
    • Mr. Robulak has had an extensive career in corporate finance with major Canadian financial institutions, more recently he provides support services for a manufacturing Company with operations in Dallas, Texas and Guadalajara, Mexico. Mr. Robulak joined the board of ALR Technologies Inc. on December , and served as chief financial officer, secretary and treasurer from April , until he resigned on January , to go to work with Morgan Stanley. Mr. Robulak earned a Bachelor of Commerce degree in finance and marketing and is a Fellow of the Institute of Canadian Bankers.
  • Alfonso Salas / Director
    • Dr. Salas graduated with distinction from Universidad Metroplitana of Barranquilla, Colombia in with a Doctor of Medicine degree. He began practicing in Santa Marta, Columbia in rural medical facilities and the opened a private practice in . He then worked as a physician with a number of shipping companies and became Medical Director in the office of the Ministry of Social Security and Labor of Columbia in doing medical assessments for work related accidents. In Dr. Salas was appointed Director of a Medical Service Plan of Columbia and with a support staff of more than thirty people, maintained a caseload, provided assessment procedures and referral services to hospitals, clinics, and specialists and organized and monitored clinical trials and clinical research in the pharmaceutical and medical field. Since Dr. Salas has operated his own business in Vancouver, British Columbia, providing medical based consulting services for corporations and agencies in Columbia with a focus on budgeting, research and medical services.
  • Peter H. Stafford / Director
    • Mr. Stafford is a retired lawyer and business consultant, having practised with Fasken Martineau DuMoulin LLP, a major Canadian based international law firm, and its predecessor firms, from to , except for several years spent as inhouse counsel for clients of the firm. Mr. Stafford s experience is in the areas of corporate and securities law, including mergers and acquisitions. From until his retirement from fulltime practice, Mr. Stafford served as senior partner in the business law department at Faskin Martineu DuMoulin LLP, including leading the start of its Johannesburg office in . Since August , Mr. Stafford has served as director, secretary and audit committee chair of Russell Breweries Inc. Formerly, he was a director and subsequently secretary of WEX Pharmaceuticals Inc. until its amalgamation, a director and board chair of BC Bancorp from until its merger with Canadian Western Bank, a director of China One Corporation until it was acquired and a director of a director of Nissho Iwai Canada Ltd. Originally from South Africa, Mr. Stafford obtained a BA from the University of Cape Town and an LL.B from the University of South Africa. He was admitted as an attorney in South Africa and subsequently was called to the English Bar Inner Temple .

Current Share Structure

  • Market Cap: $9,249,838 - 03/16/2018
  • Authorized: 500,000,000 - 02/10/2015
  • Issue and Outstanding: 242,777,909 - 02/10/2015
  • Float: 154,306,740 - 02/10/2015

 


Recent Filings from (OTC: ALRT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 28 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 23 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 02 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: February, 01 2018

 

 


Daily Technical Chart for (OTC: ALRT)

Daily Technical Chart for (OTC: ALRT)


Stay tuned for daily updates and more on (OTC: ALRT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALRT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALRT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ALRT and does not buy, sell, or trade any shares of ALRT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/